British Patient Capital has invested in Microbiotica, a personalised medicine specialist, as part of a GBP50 million Series B funding round.
The investment has been made via Future Fund: Breakthrough, British Patient Capital’s GBP375 million programme that makes co-investments with private sector investors in innovative, R&D-intensive UK companies.
The round was led by Flerie Invest and Tencent, and included Cambridge Innovation Capital, IP Group and Seventure Partners.
